SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-029378
Filing Date
2018-05-01
Accepted
2018-05-01 16:29:42
Documents
5
Period of Report
2018-05-01
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-12410_18k.htm 8-K 25074
2 EX-4.2 a18-12410_1ex4d2.htm EX-4.2 17134
3 EX-99.1 a18-12410_1ex99d1.htm EX-99.1 8502
4 GRAPHIC g124101mmi001.jpg GRAPHIC 3504
5 GRAPHIC g124101mmi002.jpg GRAPHIC 3522
  Complete submission text file 0001104659-18-029378.txt   61944
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 18795930
SIC: 2834 Pharmaceutical Preparations